CAS 1391076-61-1

Formula: C25H25ClN2O4S

InChI: InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1

InChI key: MPMKMQHJHDHPBE-RUZDIDTESA-N

SMILES: C[C@@]1(CCN1C(=O)C2=CSC3=CC=CC=C32)C(=O)N(CCCC(=O)O)CC4=CC(=CC=C4)Cl

(R)-4-(1-(Benzo[b]thiophene-3-carbonyl)-N-(3-chlorobenzyl)-2-methylazetidine-2-carboxamido)butanoic acid

CAS: 1391076-61-1

Formula: C₂₅H₂₅ClN₂O₄S

Purity: 98%

Color and Shape: Solid

Molecular weight: 484.9950

Ref: IN-DA01ENLD

GLPG0974

CAS: 1391076-61-1

GLPG0974

Formula: C₂₅H₂₅ClN₂O₄S

Purity: ≥98%

Molecular weight: 484.99

Ref: 54-BUP14309

GLPG0974

CAS: 1391076-61-1

(R)-4-(1-(Benzo[b]thiophene-3-carbonyl)-N-(3-chlorobenzyl)-2-methylazetidine-2-carboxamido)butanoic acid

Formula: C₂₅H₂₅ClN₂O₄S

Purity: 98%

Molecular weight: 485.0

Ref: IN-DG00788801

GLPG 0974

CAS: 1391076-61-1

GLPG 0974 is an experimental pharmaceutical compound, specifically an antagonist of the free fatty acid receptor 2 (FFA2), also known as GPR43. This compound is synthesized through a process of chemical engineering aimed at selectively inhibiting GPR43's activity. The mode of action involves blocking the interaction of short-chain fatty acids with GPR43, a receptor implicated in inflammatory pathways.

Formula: C₂₅H₂₅ClN₂O₄S

Purity: Min. 95%

Molecular weight: 485 g/mol

Ref: 3D-RFC07661

GLPG0974

CAS: 1391076-61-1

GLPG0974 is an antagonist of FFA2/GPR43 with IC50 of 9 nM.

Formula: C₂₅H₂₅ClN₂O₄S

Purity: 99.80%

Color and Shape: Solid

Molecular weight: 484.99

Ref: TM-T15388